NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT00000967

Locations: 🇵🇷
Univ. Hosp. Ramón Ruiz Arnau, Dept. of Peds., Bayamon, Puerto Rico
🇺🇸
St. Jude/UTHSC CRS, Memphis, Tennessee, United States
🇵🇷
San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico

and more 6 locations

A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 460

Registration Number: NCT00000949

Locations: 🇺🇸
Southern New Jersey AIDS Clinical Trials, Camden, New Jersey, United States
🇺🇸
Washington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States
🇺🇸
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States

and more 12 locations

The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 108

Registration Number: NCT00000850

Locations: 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸
Marin County Specialty Clinic, San Rafael, California, United States
🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States

and more 36 locations

A Study to Test the Safety of Three Experimental HIV Vaccines

Phase 1

Completed

Conditions: HIV Infections
HIV Seronegativity

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT00000946

Locations: 🇺🇸
Vanderbilt Univ. Hosp. AVEG, Nashville, Tennessee, United States
🇺🇸
UW - Seattle AVEG, Seattle, Washington, United States
🇺🇸
UAB AVEG, Birmingham, Alabama, United States

and more 4 locations

Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo)

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 80

Registration Number: NCT00000765

Locations: 🇺🇸
Univ of Illinois, Chicago, Illinois, United States
🇺🇸
Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
🇺🇸
Houston Clinical Research Network, Houston, Texas, United States

and more 6 locations

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

Phase 2

Completed

Conditions: HIV Infections
Toxoplasmosis, Cerebral

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT00000794

Locations: 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States

and more 13 locations

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

Phase 1

Completed

Conditions: HIV Infections
HIV Seronegativity

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 27

Registration Number: NCT00000868

Locations: 🇺🇸
JHU AVEG, Baltimore, Maryland, United States

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT00000767

Locations: 🇺🇸
JHU AVEG, Pittsburgh, Pennsylvania, United States
🇺🇸
Vanderbilt Univ. Hosp. AVEG, Nashville, Tennessee, United States
🇺🇸
Univ. of Rochester AVEG, Rochester, New York, United States

and more 2 locations

A Study to Monitor Patients With Primary or Early HIV Infection

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2015-10-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1500

Registration Number: NCT00000911

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States

Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care

Phase 3

Completed

Conditions: Chronic Granulomatous Disease

First Posted Date: 2001-08-30

Last Posted Date: 2008-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT00023192

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy